New drug combo tested for Tough-to-Treat digestive cancers
NCT ID NCT03929666
Summary
This study tested whether adding an experimental drug called ZW25 to standard chemotherapy could help control advanced stomach, bile duct, and colorectal cancers that have a specific marker called HER2. It involved 74 patients with these cancers that could not be removed by surgery. The research first checked the safety of the combination, then measured how well tumors responded to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-EXPRESSING GASTROINTESTINAL CANCERS, INCLUDING GASTROESOPHAGEAL ADENOCARCINOMA, BILIARY TRACT CANCER, AND COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
CECIM Biocinetic
Santiago, 8320000, Chile
-
Centro Internacional de Estudios Clínicos
Santiago, 8420383, Chile
-
Centro de Investigacion Clinica SAGA
Santiago, 7500653, Chile
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Icegclinic Research & Care
Santiago, 8241479, Chile
-
Korea University Anam Hospital
Seoul, 02841, South Korea
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Nebraska Methodist Hospital
Omaha, Nebraska, 68114, United States
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2C1, Canada
-
Pusan National University
Busan, 49241, South Korea
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
The Cancer and Hematology Centers
Grand Rapids, Michigan, 49503, United States
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.